Biotinylated Human LRRC15 / LIB Protein, Fc,Avitag™ (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
LR5-H82F9-25ug
$360.00
LR5-H82F9-200ug
$1565.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    Leucine-rich repeat-containing protein 15, LRRC15, LIB, hLib

  • Source

    Biotinylated Human LRRC15 Protein, Fc,Avitag (LR5-H82F9) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 538 (Accession # Q8TF66-1).

    Request for sequence
  • Molecular Characterization

    LRRC15 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 86.1 kDa. The protein migrates as 95-110 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    LRRC15 SDS-PAGE

    Biotinylated Human LRRC15 Protein, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    LRRC15 SEC-MALS

    The purity of Biotinylated Human LRRC15 Protein, Fc,Avitag (Cat. No. LR5-H82F9) is more than 90% and the molecular weight of this protein is around 185-225 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     LRRC15 ELISA

    Immobilized Samrotamab at 1 μg/mL (100 μL/well) can bind Biotinylated Human LRRC15 Protein, Fc,Avitag (Cat. No. LR5-H82F9) with a linear range of 0.2-10 ng/mL (QC tested).

    Protocol
  •  LRRC15 ELISA

    Immobilized Biotinylated Human LRRC15 Protein, Fc,Avitag (Cat. No. LR5-H82F9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Samrotamab with a linear range of 0.2-4 ng/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Recent Advances

 
Drug Development Progress
  • English Name:

    Leucine-rich repeat-containing protein 15

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    0 Details

  • Highest Development Stage:

    Preclinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8